1-2 of 2
Anita Hill, MD PhS
Close
Sort by
Journal Articles

A Prospective Analysis of Breakthrough Hemolysis in 2 Phase 3 Randomized Studies of Ravulizumab (ALXN1210) Versus Eculizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria

Robert A. Brodsky, MD, Regis Peffault De Latour, Scott T. Rottinghaus, MD, Alexander Röth, MD, Antonio M. Risitano, MD PhD, Ilene C. Weitz, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Jaroslaw P. Maciejewski, Jeffrey Szer, MBBS, Jong-Wook Lee, MD PhD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Lori Volles, MD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Lori Shafner, PhD, Anita Hill, MD PhS, Hubert Schrezenmeier, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2330.
https://doi.org/10.1182/blood-2018-99-110874
Published: 2018
Journal Articles

Results from a Phase 3, Multicenter, Non-Inferiority Study of Ravulizumab (ALXN1210) Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Eculizumab

Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Anita Hill, MD PhS, Scott T. Rottinghaus, MD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Jong-Wook Lee, MD PhD, Emilio Ojeda Gutierrez, Caroline I. Piatek, Jeffrey Szer, MBBS, Antonio M. Risitano, MD PhD, Shinji Nakao, MD PhD, Eric Bachman, Lori Shafner, PhD, Andrew I. Damokosh, PhD, Stephan Ortiz, RPh, PhD, Alexander Röth, MD, Regis Peffault De Latour
Journal: Blood
Blood (2018) 132 (Supplement 1): 625.
https://doi.org/10.1182/blood-2018-99-119147
Published: 2018